Umbilical cord mesenchymal stem cell therapy for hepatic fibrosis (Heze Biotechnology)

脐带间充质干细胞抗肝纤维化（和泽生物）

Report date: 2023/01/12 15:47:37

Base Information

Drug NameUmbilical cord mesenchymal stem cell therapy for hepatic fibrosis (Heze Biotechnology)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsLiver Cirrhosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusDiscontinued (IND)
Highest Status in ChinaDiscontinued
Originator CompaniesHeze Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesHeze Biotechnology Co Ltd
Active IndicationsN/A
Inactive IndicationsLiver Cirrhosis

Other Information

ATC CodeN/A
Related LinksN/A